Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 48-53

  Coates, L C ^a   Fransen, J ^b   Helliwell, P S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE ACTIVITY; FALSE POSITIVE RESULT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; PRIORITY JOURNAL; PSORIASIS ACTIVITY AND SEVERITY INDEX; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; RATING SCALE; SENSITIVITY AND SPECIFICITY; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; EXPERT TESTIMONY; HUMANS; OBSERVER VARIATION; PAIN MEASUREMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 73449100479     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.102053     Document Type: Article

References (15)

1. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987;62:127-41.
2. Kavanaugh AF, Ritchlin CT, GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21.
3. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263- 9.
4. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
5. Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006;24(6 Suppl 43):S-83-7.
6. Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016-24.
7. Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167- 70.
8. Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004;51:311-5.
9. Helliwell PS. GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, Stockholm, May/June 2006. J Rheumatol 2007;34:214-9.
10. Gladman DD, Farewell VT. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 1999;26:2409-13.
11. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995;22:675-9.
12. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
13. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
14. Kirwan JR, Chaput de Saintonge DM, Joyce CR, et al. Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of 'paper patients'. Ann Rheum Dis 1983;42:644-7.
15. Boers M, Brooks P, Strand CV, et al. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198-9.